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MacrophageThe anti-atherogenic cytokine, TGF-β, plays a key role during macrophage foam cell formation by modulating
the expression of key genes involved in the control of cholesterol homeostasis. Unfortunately, the molecular
mechanisms underlying these actions of TGF-β remain poorly understood. In this study we examine the ef-
fect of TGF-β on macrophage cholesterol homeostasis and delineate the role of Smads-2 and ‐3 during this
process. Western blot analysis showed that TGF-β induces a rapid phosphorylation-dependent activation of
Smad-2 and ‐3 in THP-1 and primary human monocyte-derived macrophages. Small interfering RNA-
mediated knockdown of Smad-2/3 expression showed that the TGF-β-mediated regulation of key genes im-
plicated in the uptake of modiﬁed low density lipoproteins and the efﬂux of cholesterol from foam cells was
Smad-dependent. Additionally, through the use of virally delivered Smad-2 and/or Smad-3 short hairpin
RNA, we demonstrate that TGF-β inhibits the uptake of modiﬁed LDL by macrophages through a Smad-
dependent mechanism and that the TGF-β-mediated regulation of CD36, lipoprotein lipase and scavenger
receptor-A gene expression was dependent on Smad-2. These studies reveal a crucial role for Smad signaling,
particularly Smad-2, in the inhibition of foam cell formation by TGF-β through the regulation of expression of
key genes involved in the control of macrophage cholesterol homeostasis.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Atherosclerosis is a chronic inﬂammatory disease of the vasculature
that accounts for nearly half of all mortalities in western society. This
disease is governed by many risk factors including genetic predisposi-
tion and diet, and presents itself through the appearance of ﬁbrotic
plaques in the intima of the arterial wall, that upon rupture, result in
thrombosis and ultimatelymyocardial infarction and stroke [1]. Athero-
sclerosis is initiated through the activation of the arterial endothelium
by a number of risk factors leading to the recruitment of immune
cells, particularly T lymphocytes andmonocytes. The latter differentiate
into macrophages, a process that is accompanied by increased expres-
sion of scavenger receptors, and then transform into lipid-loaded
foam cells. Formation of macrophage foam cells via the uptake of mod-
iﬁed LDL represents a critical step in atherosclerosis and is known to betein; ABCA-1, ATP-binding cas-
ansporter G-1; ApoE, apolipo-
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his work.
-NC-ND license.tightly regulated by a multitude of both novel and classical cytokines
such as interleukin (IL)-33, TNF-like protein 1A (TL1A), interferon-γ
(IFN-γ), and transforming growth factor-β (TGF-β) [2–6].
TGF-β, an extensively studied pleiotropic cytokine, is widely rec-
ognized to exert athero-protective actions. Low circulating levels of
TGF-β have been seen in patients with advanced atherosclerosis [6]
while regions of the aorta with a high probability of lesion develop-
ment, such as the dorsal descending thoracic aorta, display low levels
of TGF-β expression, thereby suggesting an inverse correlation
between TGF-β activity and the progression of the disease [7]. In
addition, inhibition of TGF-β activity and/or expression in mouse
models, achieved using neutralizing antibodies or targeted homolo-
gous gene disruption or expression of dominant negative forms of re-
ceptors, results in accelerated lesion development (in ApoE−/−mice)
and an elevated inﬂammatory response [6,8,9]. Increased atheroscle-
rosis is also observed when TGF-β signaling is speciﬁcally inhibited in
T-cells [10]. Furthermore, numerous in vitro studies from our own and
other laboratories have demonstrated that TGF-β inhibits the expres-
sion of several key genes implicated in the uptake of modiﬁed lipo-
proteins, such as scavenger receptor-A and -B1 (SR-A and SR-B1),
CD36 and lipoprotein lipase (LPL) and, simultaneously, induces the
expression of those involved in the efﬂux of cholesterol from macro-
phages such as apolipoprotein E (ApoE) and the ATP-binding cassette
transporters -A1 and -G1 (ABCA1 and ABCG1) [5,6,11–20].
Due to its involvement in the pathogenesis of many diseases, such
as arthritis, cancer and atherosclerosis, the TGF-β signal transduction
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[6,21]. Brieﬂy, TGF-β binds to its cognate heteromeric receptor complex,
composed of two type I (TGF-βRI) and type II (TGF-βRII) receptors, on
the cell surface. Phosphorylation of TGF-βRI, by TGF-βRII, on numerous
serine and threonine residues results in a conformational change in the
receptor architecture that facilitates the recruitment of Smad proteins.
Aided by the Smad anchor for receptor activation (SARA), regulatory
Smad-2 and Smad-3 become phosphorylated, complex with a common
mediator Smad-4, andmigrate to the nucleus where they canmodulate
the promoter activity of speciﬁc genes through interaction with Smad
responsive elements and/or other transcription factors [22]. In addition,
the TGF-β-mediated activation of other signaling pathways, such as
mitogen-activated protein kinases, is required for the regulation of ex-
pression of some genes by this cytokine [23,24].
Both TGF-β and Smads are known to be highly expressed in both
macrophages and foam cells of early-stage atherosclerotic lesions [25].
However, the role of Smad signaling in the TGF-β-mediated control of
macrophage foam cell formation and associated changes in gene ex-
pression is unknown except for the inhibition of CD163 expression by
this cytokine [15]. Further studies are required because of the existence
of both Smad-dependent and ‐independent pathways in TGF-β signal-
ing [26,27]. In addition, mechanistic studies examining the role of
TGF-β signaling underlying modiﬁed LDL uptake, foam cell formation
and associated changes in gene expression may ultimately open up
promising novel therapeutic avenues. Therefore, the objective of this
study was to investigate the roles of Smad-2 and Smad-3 in the TGF-
β-mediated regulation of modiﬁed LDL uptake and changes in gene ex-
pression associated with foam cell formation.
2. Materials and methods
2.1. Reagents
All chemicals were purchased from Sigma-Aldrich (Poole, U.K.)
unless otherwise stated. Recombinant human TGF-β1 was supplied
by Peprotech (London, U.K.), and 1,1′-dioctadecyl-3,3,3′,3′-tetra-
methyllindocarbocyane perchlorate (DiI)-labeled acetylated LDL
(DiI-AcLDL) and (DiI)-labeled oxidized LDL (DiI-OxLDL) were pur-
chased from Intracel (Frederick, MD, USA).
2.2. Cell culture
Human monocyte-derived macrophages (HMDM) were
differentiated from monocytes isolated from buffy coats supplied by
the Welsh Blood service using Ficoll-Hypaque puriﬁcation described
elsewhere [2]. Ethical approval and informed consent for each
donor was granted by the Welsh Blood Service for the use of human
blood samples. Human acute monocytic leukemia cell line (THP-1)
and HMDM were grown in complete RPMI-1640 supplemented
with 10% (v/v) (THP-1) or 5% (v/v) (HMDM) (v/v) heat-inactivated
FCS (heated to 56 °C for 30 minutes), penicillin (100 U/ml), streptomycin
(100 μg/ml) and L-glutamine (2 mmol/l) at 37 °C in a humidiﬁed atmo-
sphere containing 5% (v/v) CO2. THP-1 monocytes were differentiated
intomacrophages using 160 nMPMA for 24 hours to ensure high expres-
sion levels of scavenger receptors and other genes implicated in the
control of macrophage foam cell formation [28]. In all experiments,
unless otherwise stated, cells were incubated with TGF-β (30 ng/ml) for
48 hours. Recombinant human TGF-β was reconstituted in PBS/0.1%
BSA that was subsequently used as a vehicle control.
2.3. LDL uptake assays
Cells were incubated for 24 or 48 hours with DiI-AcLDL or DiI-
OxLDL (10 μg/ml; Intracel, Frederick, MD) in RPMI-1640 containing
0.2% (v/v) fatty acid free BSA at 37 °C. The uptake of modiﬁed LDL
was analyzed by ﬂow cytometry on a FACS Canto ﬂow cytometer(BD Biosciences, Oxford, U.K.) with at least 10,000 events acquired
for each sample. Data were represented as a percentage of the
vehicle-treated control cells.
2.4. Real-time quantitative PCR
RNA extraction, reverse transcription and real-time quantitative
PCR analysis were performed as described elsewhere [2]. Oligonucle-
otides sequences can be seen in supplementary Table I and were pur-
chased from Sigma Aldrich (Poole, UK). Fold changes in expression
were calculated using 2−(ΔCt1−ΔCt2), where ΔCt represents the differ-
ence between the threshold cycle (CT) for each target gene and
housekeeping mRNA transcript levels. Melting curve analysis was
performed on each primer set to conﬁrm ampliﬁcation of a single
product and all amplicons were sequenced to ensure reaction speci-
ﬁcity (data not shown).
2.5. Western blotting
Total cell lysates were size-fractionated and analyzed by Western
blotting as previously described [2,3,5,16,21]. Samples were subjected
to electrophoresis alongside comparative molecular weight markers
(GE Healthcare, WI, USA) to determine the size of the protein product.
Antibodies speciﬁc to Phosho-Smad 2 (#3108), Phospho-Smad 3
(#9520), Total-Smad 2 (#5339), Total-Smad 3 (#9523) and Total-
Smad 2/3 (#3102) were supplied by Cell Signaling Technologies (Dan-
vers, MA, USA). Antibodies speciﬁc to ApoE (0650–1904), SR-A (sc-
20660) and β-Actin were supplied by Biogenesis (Poole, U.K.), Santa
Cruz Biotechnology (Santa Cruz, CA) and Sigma (Poole, UK)
respectively.
2.6. Transfection of siRNA
THP-1 monocytes were transfected with validated small interfering
(si)RNAs speciﬁc for Smad-2 and Smad-3 or glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (used as control; see supplementary
Fig. 2) for a ﬁnal concentration of 7.5 nM using INTERFERin™ in
accordance with the manufacturer's protocol (PolyPlus Transfection).
The cells were then left for 24 hours, differentiated into macrophages by
incubationwith 160 nMPMA for 24 hours as described above, and subse-
quently treated with TGF-β or vehicle for 24 hours. Gene silencing was
measured by Western blotting.
2.7. Generation of adenovirus encoding Smad-2, Smad-3 and GAPDH shRNA
Adenovirus type 5 (Ad5) vectors were engineered to express Smad-
2, Smad-3 or GAPDH short hairpin (sh)-RNA ﬂanked by sequences from
the mouse BIC gene (+134/+161 and +221/+265, AY096003) to
enable the shRNA to be processed by the endogenous microRNA
(miRNA) cellular machinery as previously described [29]. Appropriate
shRNAs, targeting the following sequences of the Smad-2 gene:
AAGAGCAGCAAATTCCTGGTT (Rad-Smad 2 shRNA) or the Smad-3
gene: TCCATCTTCACTCAGGTAGCC (Rad-Smad 3 shRNA) or the
GAPDH gene: AGAAGATGCGGCTGACTGTCG (Rad-GAPDH shRNA),
were inserted into the Ad5 vector using recombineering technology as
described elsewhere [30]. Brieﬂy, two oligonucleotides (detailed in sup-
plementary Table II) that overlap by 25 base pairs at their 3′ and 5′ ends
respectively were designed to contain the appropriate shRNA sequence
and arms of homology to facilitate homologous recombination into the
Ad5 vector. Induced Escherichia coli SW102 containing the Ad5 vector
genome in a modiﬁed bacterial artiﬁcial chromosome (BAC) were
transformed with each oligonucleotide (100 ng) and appropriate rec-
ombinants were identiﬁed by sequence analysis. Adenoviruses were
then ampliﬁed, puriﬁed and tittered as described elsewhere [30].
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Fig. 1. Activation and silencing of Smad-2 and ‐3 in human macrophages. (A) Smad-2 phosphorylation or Smad-3 phosphorylation was determined in HMDM either left untreated
(empty bars) or incubated with TGF-β (30 ng/ml; ﬁlled bars) for 60 minutes. Equal amounts of protein extracts were subjected toWestern blot analysis using antisera against phos-
phorylated (P-)Smad 2, P-Smad 3 or total (T-)Smad 2/3. P-Smad 2 and P-Smad 3 levels were normalized to T-Smad 2/3 expression and displayed as a fold change compared to
untreated controls (arbitrarily assigned as 1). Data represent the mean±SD of 3 or 5 independent experiments (P-Smad 2 and P-Smad 3 respectively). (B) The expression of
GAPDH or total (T-)Smad 2/3 protein was knocked down in untreated THP-1 macrophages (UT, empty bars) or those incubated with TGF-β (30 ng/ml; TGF-β, ﬁlled bars) using
gene speciﬁc siRNA transfection. Equal amounts of protein extracts were subjected to Western blot analysis using antisera against T-Smad 2/3 or β-Actin. T-Smad 2/3 levels
were normalized to β-actin expression and are displayed as a fold change compared to GAPDH siRNA controls (arbitrarily assigned as 1). Data represent the mean±SD of 3 inde-
pendent experiments. Statistical analysis was performed using the Student's t-test, * Pb0.05.
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THP-1 monocytes or HMDM were infected with Rad-GAPDH
shRNA or Rad-Smad 2 shRNA or Rad-Smad 3 shRNA at a multiplicity
of infection (MOI) of 100 for each virus in 0.5 ml RPMI-1640 medium
for 2.5 hours at 37 °C (rocking) prior to addition of 1 ml RPMI-1640
medium (including 160 nM PMA for THP-1 monocytes to induce dif-
ferentiation into macrophages) and incubation for a further 72 hours.
Macrophages were then stimulated with TGF-β or vehicle control for
48 hours. An MOI of 100 was sufﬁcient to infect >90% THP-1 cells as
measured by ﬂow cytometry following infection with a GFP-
expressing recombinant adenovirus (data not shown).
2.9. Statistical analysis
All data are presented as mean [±standard deviation (SD)] on the
assigned number of independent experiments or, in experiments in-
volving HMDM, experiments performed using samples from different
donors. For single comparisons, values for p were calculated using the
Student's t-test. For multiple comparisons, values of p were calculated
using one-way ANOVA with Tukey's post-hoc analysis where homoge-
neity of variance was met (as determined by Levene's test of homoge-
neity of variances) or Welch's robust test of equality of means
followed by Games–Howell post-hoc analysis. Values of pwere consid-
ered signiﬁcant below 0.05.3. Results
3.1. TGF-β modulates the expression of key genes implicated in the up-
take and efﬂux of cholesterol through a Smad-dependent mechanism
PMA differentiated THP-1 cells are commonly used as a model to
delineate human macrophage cellular functions and gene expression
associated with atherosclerosis in the light of their conserved re-
sponses with primary HMDM and in vivo evidence [2,3,31]. This cellu-
lar system was therefore employed to examine the potential role of
Smad signaling in the TGF-β-mediated regulation of macrophage cho-
lesterol homeostasis and foam cell formation in human macrophages.
Key ﬁndings were conﬁrmed in primary cultures of HMDM.
Weﬁrst examined the ability of TGF-β to activate the Smad signaling
cascade in human macrophages. Previous studies by our group have
shown that 30 ng/ml of TGF-β inducesmaximal changes inmacrophage
gene expression [5,16,21]. We therefore performed all experiments
using this previously established concentration. As shown in Fig. 1A,
both Smad-2 and ‐3 were rapidly phosphorylated (and therefore acti-
vated) after 60 minutes incubation with TGF-β in HMDM. Supplemen-
tary Fig. 1 shows that this response was rapid and sustained, albeit at
varying levels, for 3 hours and conﬁrms that the TGF-β-mediated acti-
vation of Smad-2 and ‐3 was conserved in THP-1 macrophages.
Many studies have reported a TGF-β-mediated reduction in the ex-
pression of key genes involved in the uptake ofmodiﬁed lipoproteins by
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Fig. 2. TGF-β regulates the expression of key genes implicated in the control of cholesterol homeostasis in human macrophages through a Smad-dependent pathway. The expres-
sion of total (T-)Smad 2/3 or GAPDH protein in THP-1 macrophages was knocked down using gene speciﬁc siRNA transfection (as seen in Fig. 1B). The cells were then either left
untreated (UT, empty bars) or stimulated (TGF-β, ﬁlled bars) with 30 ng/ml of TGF-β for 6 hours (ABCA1 and ABCG1) or 24 hours (other genes). Total RNA was subjected to real-
time quantitative PCR using primers against (A) LPL, CD36, SR-A, SR-B1 or (B) ABCG-1, ABCA-1 and ApoE as indicated. The mRNA expression levels were calculated using compar-
ative Ct method and normalized to 28S ribosomal (r)RNA levels (or RPL13A for ABCA-1 and ABCG-1) with untreated cells given an arbitrary value of 1. Data represent the mean±SD
of 3 independent experiments. (C) Equal amounts of protein extracts were subjected to Western blot analysis using antisera against SR-A, ApoE or β-actin as indicated. Protein ex-
pression, as determined by densitometric analysis, was normalized to β-actin and is displayed as a fold change compared to the untreated controls (arbitrarily assigned as 1). Data
represent the mean±SD of 3 independent experiments. Multiple immunoreactive polypeptides for SR-A represent different isoforms that are known to be produced by alternative
splicing. In all cases, statistical analysis was performed using the Student's t-test, * Pb0.05; ** Pb0.01. NS indicates not signiﬁcant.
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duction of those implicated in cholesterol efﬂux, such as ApoE, ABCA1
and ABCG1 [5,19,20]. Unfortunately, the role of Smad-2 and ‐3 in the
TGF-β-mediated regulation of expression of these genes is poorly un-
derstood and was therefore investigated ﬁrst using a dual-Smad2/3
siRNA-mediated knockdown assay in THP-1 macrophages. Compari-
sons were made with knockdown of GAPDH, which has been used as
a control in numerous previous studies [32–36]. As shown in Fig. 1B,
transfection of THP-1 cells with a combination of Smad-2 and ‐3 speciﬁc
siRNAs resulted in a signiﬁcant knockdown of total (T)-Smad 2/3 pro-
tein expression in both TGF-β treated and untreated cells when com-
pared to control GAPDH siRNA transfected cells. In all cases, the TGF-
β-mediated changes in the expression of genes studied were seen in
cells transfected with GAPDH siRNA thus conﬁrming the ﬁdelity of our
siRNA system. The decrease in GAPDH expression following siRNA-mediated knockdown of this gene was conﬁrmed by RT-PCR (see sup-
plementary Fig. 2).
As shown in Fig. 2A and B, consistent with published literature
[5,6,12–14,16–20], the expression of key genes involved in cholester-
ol uptake (LPL, CD36, SR-A and SR-B1) were signiﬁcantly inhibited by
TGF-β in GAPDH transfected THP-1 macrophages, while those in-
volved in cholesterol efﬂux (ABCA1, ABCG1 and ApoE) were signiﬁ-
cantly induced. In contrast to this, the ability of TGF-β to replicate
these responses was abolished in Smad-2/3 depleted cells as shown
by the non-signiﬁcant changes in transcript level observed for each
gene compared to GAPDH siRNA transfected cells, thereby suggesting
that Smad signal transduction plays an integral role in the regulation
of expression of these genes. Smads are transcription factors and the
changes in mRNA expression of downstream genes, such as LPL and
ApoE, are reﬂective of their functional actions. Numerous studies by
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Fig. 3. TGF-β inhibits modiﬁed LDL uptake by human macrophages. (A) DiI-OxLDL
uptake is shown in THP-1 macrophages either left untreated (empty bars) or incubated
with TGF-β (30 ng/ml: ﬁlled bars) for 24 hours. Data represent the mean±SD of 4 in-
dependent experiments, or DiI-AcLDL uptake is shown in THP-1 macrophages
either left untreated (empty bars) or incubated with TGF-β (30 ng/ml: ﬁlled bars) for
(B) 24 hours or (C) 48 hours. Data represent the mean±SD of 6 independent experi-
ments. Relative modiﬁed LDL uptake is displayed as a % of untreated controls (arbi-
trarily assigned as 100%). Statistical analysis was performed using the Student's t-test;
*** Pb0.001.
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expression of LPL, SR-A, SR-B1, CD36, ApoE, ABCA1 and ABCG1 tran-
scripts and their protein levels in both THP-1 macrophages and
HMDMs suggesting that any changes in mRNA expression observed
for these genes are likely to be conserved at protein levels [2,5,21].
Nevertheless, this was conﬁrmed by Western blot analysis of selected
proteins in an identical knockdown system. As shown in Fig. 2C, the
TGF-β-mediated modulation of expression of SR-A (all 3 isoforms)
and ApoE, was abrogated in response to Smad-2/3 knockdown.
3.2. TGF-β reduces modiﬁed LDL uptake in THP-1 macrophages through a
Smad-dependent mechanism
In order to determine if the changes observed in gene expression
impart an observable change in cellular lipid uptake, we examined
the effect of exogenous TGF-β stimulation on the uptake of OxLDL
and AcLDL, both of which are commonly used to perform in vitro
foam cell formation assays [2,3,37,38]. DiI-labeled LDLs were used at
concentrations reﬂecting those employed in other published in vitro
studies [2,3] and, similar to several previous publications [39–43],
the effect of TGF-β on the uptake of modiﬁed LDL was represented
relative to control cells. As shown in Fig. 3A, incubation of the cells
with TGF-β for 24 hours produced an approximate 25% reduction in
OxLDL uptake. Interestingly, both 24 and 48 hour TGF-β stimulation
with AcLDL resulted in a slightly greater 30% reduction in DiI-AcLDL
uptake (Fig. 3B and C respectively). The magnitude of these reduc-
tions exceeds that seen for other anti-atherogenic cytokines in identi-
cal systems, such as IL-33 [2], suggesting that TGF-β plays a key role
in the inhibition of foam cell formation.
The involvement of Smad-2 and Smad-3 in this process was
subsequently analyzed using THP-1 cells expressing adenoviral deliv-
ered shRNAs that facilitate the speciﬁc knockdown of Smad-2 or
Smad-3 transcript levels; approximately 94% and 87% reductions re-
spectively (Fig. 4A) translate into approximately 84% (T-Smad 2)
and 88% (T-Smad 3) reductions in protein level (Fig. 4B). TGF-β stim-
ulation had no signiﬁcant effect on T-Smad protein levels. It should be
noted that in all experiments hereafter a virally infected shRNA sys-
tem was adopted due to the improved level of gene silencing ob-
served compared to our siRNA system (Fig. 1B). In addition, in
another study of a similar nature on death receptor 3 (DR3) we had
shown that the changes in foam cell formation and the expression
of downstream genes following knockdown of DR3 was similar to
those seen using bone marrow-derived macrophages from DR3
knockout mice [3]. The duration of TGF-β treatment was increased
to 48 hours in accordance with maximal AcLDL uptake in our virally
infected system. As shown in Fig. 4C, comparison of cytokine treated
and untreated cells shows that the TGF-β-mediated reduction in
AcLDL uptake in the GAPDH shRNA infected control was attenuated
in cells deﬁcient in both Smad-2 and Smad-3 expression, and similar-
ly, in cells deﬁcient in Smad-2 or Smad-3 expression (Fig. 4D). It must
be noted that a reduced magnitude in AcLDL uptake was observed in
the GAPDH shRNA infected control cells (Fig. 4C and D) when com-
pared to uninfected cells (Fig. 3C). Despite this slightly attenuated re-
sponse, which could be attributed to the infection process, these data
suggest that TGF-β inhibits the uptake of AcLDL and that this process
was dependent on Smad-2 and Smad-3.
3.3. TGF-β alters the expression of key genes involved in macrophage
cholesterol uptake through a Smad-2-dependent mechanism
In order to conﬁrm that the regulation of key genes involved in
macrophage cholesterol uptake is Smad-dependent, and to determine
if Smad-2 and Smad-3 play distinct roles in this process, we next ex-
amined the transcript levels of CD36, LPL and SR-A in our Smad
depleted, TGF-β stimulated virally infected system. As already dis-
cussed, efﬁcient silencing of Smad mRNA and protein expressionwas achieved using Rad-Smad shRNA infection of THP-1 cells
(Fig. 4A and B). As shown in Fig. 5, a statistically signiﬁcant reduction
in the expression of CD36 (Fig. 5A), LPL (Fig. 5B) and SR-A (Fig. 5C)
transcripts were observed in TGF-β treated, GAPDH shRNA infected
cells when compared to the untreated GAPDH shRNA infected cells
thus corroborating our previous ﬁndings. Furthermore, Smad-2
shRNA infection abolished the TGF-β responsiveness for all tran-
scripts examined while Smad-3 depleted THP-1 macrophages
maintained their ability to signiﬁcantly down regulate CD36 and SR-
A mRNA expression (Fig. 5A and C) in response to TGF-β. It should
be noted that despite not reaching signiﬁcance, TGF-β stimulation
did induce a trend towards a decrease in LPL mRNA expression in
Smad-3 depleted cells. Silencing of both Smad-2 and ‐3 in THP-1mac-
rophages also abolished the responsiveness of these genes to TGF-β-
mediated inhibition (Fig. 5).
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ry cells, representative experiments were performed in HMDM.
Fig. 6A illustrates effective silencing of Smad-2 (86%) and Smad-3
(66%) gene expression in HMDM and, interestingly, in these cells
Smad-2 knockdown can be seen to induce a non-signiﬁcant 2-fold in-
crease in Smad-3 expression. As in the case of THP-1 cells, TGF-βstimulation reduced the expression of CD36 and LPL in Rad-GAPDH
shRNA infected cells (Fig. 6B and C). Likewise, knockdown of Smad-
2 expression resulted in a marked attenuation of TGF-β responsive-
ness for both CD36 and LPL expression. In addition, a similar effect
was seen following knockdown of both Smad-2 and Smad-3. Further-
more, a statistically signiﬁcant reduction of CD36 and LPL mRNA
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1614 D.R. Michael et al. / Biochimica et Biophysica Acta 1822 (2012) 1608–1616expression was still observed when the expression of only Smad-3
was knocked down. Overall, these data conﬁrm that TGF-β can
down regulate the expression of key genes involved in the uptake of
cholesterol and suggests that this process is mainly dependent on
Smad-2 and not Smad-3 signaling.
4. Discussion
The formation and accumulation of lipid engorged foam cells in
the intima of the arterial wall is the key occurrence during the devel-
opment of atherosclerosis [44]. It is understood that TGF-β can inhibit
macrophage foam cell formation by regulating the expression of clas-
sic lipoprotein uptake and efﬂux genes [45]. However, the molecular
mechanisms underlying such regulation is poorly understood and
Smads have been shown to be required for the action of TGF-β ononly a single gene, CD136 [15]. Further studies are necessary because
of the existence of Smad-dependant and ‐independent mechanisms
for the action of this cytokine [26,27]. In this study, for the ﬁrst
time, we clearly demonstrate that the Smad signal transduction path-
way plays a critical role during TGF-β-mediated modulation of key
cholesterol uptake (LPL, SR-A, SR-B1 and CD36) and efﬂux genes
(ApoE, ABCA1 and ABCG1), and that this response is accompanied
by a Smad-dependant reduction in AcLDL uptake in macrophages.
1615D.R. Michael et al. / Biochimica et Biophysica Acta 1822 (2012) 1608–1616These ﬁndings provide novel insights into the mechanisms underly-
ing the TGF-β regulation of foam cell formation.
TGF-β, its receptors and Smads are all known to be expressed by
macrophages in early stage atherosclerotic lesions present in human
aortas [25]. Following arterial injury or activation, TGF-β is converted
from a latent precursor to an activated form by a group of calcium-
dependent proteases called furin-like proprotein convertases [46].
Active forms of Smad-2 and ‐3 have also been shown to exist in aortic
lesions of atherosclerotic ApoE deﬁcient mice [47], although it is
unclear whether Smad activation occurs in response to arterial injury
in humans. To this end, we have shown that Smad-2 and ‐3 are rapid-
ly phosphorylated (and therefore activated) in response to TGF-β in
both THP-1 macrophages and HMDM (Fig. 1A and supplementary
data). The Smad signaling pathway has also been shown to be active
in human atherosclerotic lesions suggesting that macrophages pre-
sent in such lesions are TGF-β/Smad signaling sensitive [48].
Despite the establishment of Smads as classical transducers of the
TGF-β signal, little is known about their role during the regulation of
macrophage cholesterol homeostasis. Using siRNA knockdown of
Smad-2 and ‐3 in THP-1 macrophages, we initially demonstrated
that the Smad signaling pathway (Smad-2 and ‐3 together) was cru-
cial for the TGF-β-induced expression of ApoE, ABCA1 and ABCG1 and
also for the TGF-β-mediated inhibition of LPL, SR-A, CD36 and SR-B1
expression (Fig. 2). More detailed examination, using a more robust
and speciﬁc viral shRNA system, demonstrated that the Smad signal-
ing cascade plays a crucial role during the TGF-β-mediated inhibition
of AcLDL uptake by macrophages (Fig. 4) and highlighted the Smad-2
dependency of CD36, SR-A and to some extent LPL gene expression in
THP-1 macrophages and that of CD36 and LPL in HMDM (Figs. 5 and
6). Considering the involvement of Smad-2 during the TGF-β-
mediated inhibition of CD36, a major scavenger receptor for OxLDL,
these data also suggest that the TGF-β-mediated inhibition of OxLDL
uptake (Fig. 3A) may also be mediated by a Smad-2 dependent
mechanism.
Interestingly, as seen during the knockdown of Smad-2 expression
in NIH/3T3 ﬁbroblast cell line [49], depletion of Smad-2 expression in
HMDM results in a non-signiﬁcant increase in Smad-3 expression
(Fig. 6A) suggesting that a compensatory mechanism may exist be-
tween Smad-2 and Smad-3 expression. Despite this, a TGF-β-
mediated reduction in the expression of CD36 and LPL in HMDM
was not signiﬁcant in Smad-2 (or both Smad-2 and Smad-3) depleted
cells (Fig. 6). In contrast, a statistically signiﬁcant reduction in the ex-
pression of these genes was seen in Smad-3 depleted cells, thereby
substantiating the dominant role of Smad-2.
The emergence of Smad-2 as the key player in the process of mac-
rophage lipid accumulation may not appear surprising given the su-
perior levels of activated Smad-2 compared to Smad-3 seen in both
THP-1 macrophages and HMDM (Fig. 1 and supplementary data), al-
though the majority of existing evidence does suggest that Smad-3 is
the functionally dominant TGF-β signal transducer [50,51]. However,
it has now become apparent that Smad-2 can act as the dominant
component of the TGF-β signal transduction in many cellular systems
[22]. One of the key differences between the two Smads is the ability
of Smad-3 to bind directly to DNA through its MH1 domain while
Smad-2 requires Smad-4 for DNA binding due to a 30 amino-acid in-
sert in this domain [22]. This difference may be important in the reg-
ulation of genes involved in macrophage cholesterol homeostasis and
foam cell formation.
5. Conclusion
In conclusion, we have demonstrated for the ﬁrst time that the
Smad signaling pathway, particularly Smad-2, plays a crucial role in
the control of macrophage cholesterol uptake and expression of key
genes implicated in this process by TGF-β. Our ﬁndings, along with
the ability of TGF-β to increase the expression of key macrophagecholesterol efﬂux genes (Fig. 2) and cellular cholesterol efﬂux, as
shown elsewhere [18–20], indicate that TGF-β has substantial anti-
foam cell properties and highlight its potential as a powerful anti-
foam cell therapeutic tool for the future.
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